Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision vs Conventional Treatment in Active Takayasu's Arteritis
NCT06498089Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of tocilizumab, tofacitinib oral solution, adalimumab in Takayasu's arteritis (TAK), sponsored by Zhongshan Hospital, Fudan University. Started Jun 2024; status: recruiting.
02
Drugs
03
Conditions
Takayasu's arteritis (TAK)
Beyond the preview
Go deeper on NCT06498089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06498089.